A Phase lb Dose Escalation Trial of R04929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER plus Metastatic Breast Cancer.

被引：3
|
作者：
Means-Powell, J. A.
Minton, S. E.
Mayer, I. A.
Abramson, V. G.
Ismail-Khan, R.
Arteaga, C. L.
Ayers, D. A.
Sanders, M. S.
Lush, R. M.
Miele, L.
机构：
[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[2] Moffit Canc Ctr, Tampa, FL USA
[3] Univ Mississippi, Hlth Care Canc Inst, Jackson, MS 39216 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P2-14-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-14-04
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER plus Metastatic Breast Cancer (MBC)
    Means-Powell, Julie A.
    Mayer, Ingrid A.
    Ismail-Khan, Roohi
    Del Valle, Luis
    Tonetti, Debra
    Abramson, Vandana G.
    Sanders, Melinda S.
    Lush, Richard M.
    Sorrentino, Claudia
    Majumder, Samarpan
    Miele, Lucio
    CLINICAL BREAST CANCER, 2022, 22 (02) : 103 - 114
  • [2] A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
    Richter, Suzanne
    Bedard, Philippe L.
    Chen, Eric Xueyu
    Clarke, Blaise A.
    Tran, Ben
    Hotte, Sebastien J.
    Stathis, Anastasios
    Hirte, Hal W.
    Razak, Albiruni R. A.
    Reedijk, Michael
    Chen, Zhuo
    Cohen, Brenda
    Zhang, Wen-Jiang
    Wang, Lisa
    Ivy, S. Percy
    Moore, Malcolm J.
    Oza, Amit M.
    Siu, Lillian L.
    McWhirter, Elaine
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 243 - 249
  • [3] A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
    Richter, Sue
    McWhirter, Elaine
    Chen, Eric Xueyu
    Ben Tran
    Hotte, Sebastien J.
    Stathis, Anastasios
    Hirte, Hal W.
    Razak, Albiruni R. A.
    Laughlin, Anne
    Wang, Lisa
    Battista, Kristina
    Stayner, Lee-Anne
    Ivy, S. Percy
    Moore, Malcolm J.
    Oza, Amit M.
    Siu, Lillian L.
    Bedard, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
    Suzanne Richter
    Philippe L. Bedard
    Eric Xueyu Chen
    Blaise A. Clarke
    Ben Tran
    Sebastien J. Hotte
    Anastasios Stathis
    Hal W. Hirte
    Albiruni R. A. Razak
    Michael Reedijk
    Zhuo Chen
    Brenda Cohen
    Wen-Jiang Zhang
    Lisa Wang
    S. Percy Ivy
    Malcolm J. Moore
    Amit M. Oza
    Lillian L. Siu
    Elaine McWhirter
    Investigational New Drugs, 2014, 32 : 243 - 249
  • [5] Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
    Bayet-Robert, Mathilde
    Kwiatkowski, Fabrice
    Leheurteur, Marianne
    Gachon, Francoise
    Planchat, Eloise
    Abrial, Catherine
    Mouret-Reynier, Marie-Ange
    Durando, Xavier
    Barthomeuf, Chantal
    Chollet, Philippe
    CANCER BIOLOGY & THERAPY, 2010, 9 (01) : 8 - 14
  • [6] Phase II trial of goserelin and exemestane combination therapy in premenopausal women with locally advanced or metastatic breast cancer.
    Wang, Jiayu
    Xu, Binghe
    Yuan, Peng
    Ma, Fei
    Li, Qing
    Zhang, Pin
    Luo, Yang
    Cai, Ruigang
    Fan, Ying
    Li, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer.
    Cobleigh, MA
    Miller, KD
    Langmuir, VK
    Reimann, JD
    Vassel, AV
    Novotny, WF
    Sledge, GW
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 301 - 301
  • [8] A phase I trial of the farnesyl transferase inhibitor tipifarnib plus doxorubicin-cyclophosphamide in patients with metastatic breast cancer.
    Sparan, JA
    Hopkins, U
    Moulder, S
    Vahdat, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 46S - 46S
  • [9] Phase lb Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer
    Schott, A. F.
    Chang, J. C.
    Krop, I. E.
    Griffith, K. A.
    Layman, R. M.
    Hayes, D. F.
    Wicha, M. S.
    CANCER RESEARCH, 2010, 70
  • [10] Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER plus metastatic breast cancer.
    Rosen, Ezra
    Sharma, Manish
    Berz, David
    Caswell-Jin, Jennifer Lee
    Spira, Alexander I.
    Fulgar, Georgina A.
    Densel, Mark
    Rana, Nawaid
    Sperry, Samuel
    Warner, Douglas
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345